Skip to main content
PharmaGraphX
PharmaGraphX
Log inGet Started

Important Disclaimer

PharmaGraphX is a research and educational tool only. It is NOT intended for clinical decision-making, patient care, or medical advice. All drug information, calculations, interactions, and recommendations are for educational and research purposes only. Always consult qualified healthcare professionals, official drug labeling (FDA, TGA, EMA), and institutional guidelines before making any clinical decisions. The developers assume no liability for any decisions made based on information provided by this platform.

© 2026 PharmaGraphX. All rights reserved.

|

For research and educational purposes only. Not medical advice.

Help
  • Navigate between workspaces using the left sidebar.
  • Use the main chat to ask any pharmacology question.
  • Press G then H to quickly navigate home.
Navigation
HomeG H
PK/PD StudioG P
Interaction HubG A
Digital TwinG T
Molecular LabG M

Press Esc to close

  1. Home
  2. /Database
  3. /Imatinib

Imatinib

Gleevec, Imkeldi

Antineoplastic • Tyrosine kinase inhibitor

Premium
QT RiskHepatotoxicNephrotoxic

Half-life

18 hours (40 hours for active metabolite)

Protein Binding

Metabolized By

CYP3A4, CYP1A2, CYP2D6, CYP2C9, CYP2C19

External

Drugs.com

Mechanism of Action

Inhibits BCR-ABL, c-KIT, and PDGFR tyrosine kinases

Indications(5)

GISTGastrointestinal Stromal Tumor(GIST)Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveMinimal Residual DiseaseGastrointestinal Neoplasms

Classification

Drug Class

Antineoplastic

Subclass

Tyrosine kinase inhibitor

Brand Names

GleevecImkeldi

Key Properties

Half-life

18 hours (40 hours for active metabolite)

Time for plasma concentration to decrease by 50%

Protein Binding

—

Fraction bound to plasma proteins

Therapeutic Index

Wide

Margin between therapeutic and toxic doses

Not a substitute for clinical judgement
Imatinib Drug Profile | PharmaGraphX